Blog of Signaling Pathways

Identification of the stable and reactive metabolites of tetrahydropiperine using ultrahigh-performance liquid chromatography combined with diode-array detection and high-resolution mass spectrometry

8 views | May 01 2023

The study aimed to investigate the metabolic profiles of tetrahydropiperine in various species of hepatocytes, and the results showed that it was bioactivated through ortho-quinone, Michael receptor, and aldehyde intermediates, with major metabolic pathways being hydroxylation, dehydrogenation, methylation, GSH conjugation, and glucuronidation. [Read the Full Post]

A large-scale functional analysis of genes expressed differentially in insulin secreting MIN6 sublines with high versus mildly reduced glucose-responsiveness

51 views | May 01 2023

This study identified 18 genes that altered glucose-stimulated insulin secretion (GSIS) in pancreatic β-cells, and confirmed Sox11 as a negative regulator of insulin secretion and its role in glucose metabolism. [Read the Full Post]

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver-child dyads' perspective

90 views | May 01 2023

The study found that caregivers in Uganda found the new 4-in-1 strawberry-flavoured granules formulation highly acceptable for children living with HIV compared to previous formulations, with factors such as appealing taste, ease of administration, and comprehensive healthcare provider support contributing to its acceptability. [Read the Full Post]

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

21 views | May 01 2023

The study found that the 2-drug regimen of dolutegravir (DTG) + lamivudine (3TC) offers comparable and durable efficacy with fewer serious adverse events compared to two 3-drug single-tablet regimens in antiretroviral therapy-naive people with HIV-1 at Week 144 after treatment initiation. [Read the Full Post]

Factors Associated With Adherence to First-line Antiviral Therapy Among Commercially Insured Patients With Chronic Hepatitis B

24 views | May 01 2023

The study found that longer-duration supplies of entecavir and TDF and use of mail order pharmacies may improve adherence among patients with CHB, while high out-of-pocket costs for TDF were associated with reduced medication adherence. [Read the Full Post]

Effect of FTY-720 on Pulmonary Fibrosis in Mice via the TGF-β1 Signaling Pathway and Autophagy

25 views | Apr 30 2023

FTY-720 was found to inhibit the TGF-β1 pathway and up-regulate autophagy, resulting in attenuation of disorganization of alveolar tissue and collagen deposition, and reduced levels of inflammatory cytokines and protein expressions in lung tissue, indicating its potential as a treatment target for pulmonary fibrosis. [Read the Full Post]

Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?

26 views | Apr 30 2023

FTY720, an FDA-approved drug for the treatment of multiple sclerosis, shows promise in reversing synaptic deficits and memory dysfunction in Alzheimer's disease mouse models, and could be a potential disease modifying anti-AD drug. [Read the Full Post]

Fk506 Inhibit liver regeneration in HOC model Rat

127 views | Apr 30 2023

The study found that FK506 inhibits HOC activation and proliferation, ultimately blocking liver regeneration and highlighting the importance of understanding the role of lymphocytes in liver regeneration and the clinical use of FK506 in liver transplantation. [Read the Full Post]

Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets

53 views | Apr 30 2023

Tuberculosis (TB) caused by Mycobacterium tuberculosis is a global health concern that requires the development of new anti-TB drugs due to the emergence of drug-resistant strains and the challenges of current treatment protocols. [Read the Full Post]

Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design

33 views | Apr 30 2023

The proposed method is a green, rapid, and simple RP-UPLC method developed and optimized by full factorial design for the simultaneous separation of oseltamivir phosphate, daclatasivir dihydrochloride, and remdesivir, with dexamethasone as a co-administered drug, and it demonstrated linearity, precision, and accuracy with low limits of quantitation and detection, and high percentage recoveries, making it an eco-friendly and efficient analytical procedure. [Read the Full Post]

The Mystery of EVP4593: Perspectives of the Quinazoline-Derived Compound in the Treatment of Huntington's Disease and Other Human Pathologies

114 views | Apr 29 2023

EVP4593, a quinazoline derivative, has shown potential as a therapeutic agent in various pathologies, including Huntington's disease, by modulating calcium signaling and reducing the levels of specific proteins. [Read the Full Post]

Maslinic Acid Ameliorates Myocardial Ischemia Reperfusion Injury-Induced Oxidative Stress via Activating Nrf2 and Inhibiting NF-[Formula: see text]B Pathways

42 views | Apr 29 2023

The study found that maslinic acid has potent antioxidative properties and exerts its cardioprotective effect through activating the Nrf2/HO-1 pathway and inhibiting NF-κB activation, indicating its potential therapeutic use in the treatment of myocardial ischemia-reperfusion injury and other conditions associated with oxidative stress and inflammation. [Read the Full Post]

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats

41 views | Apr 29 2023

The study investigated the effect of six drugs on the transport of gadoxetate in rats using PBPK modelling and tracer-kinetic models, demonstrating a framework for prospective quantification of hepatic transporter-mediated DDI in humans. [Read the Full Post]

Analysis of Hepatitis C Virus Resistance-Associated Substitutions in Direct-Acting Antiviral Failure in South Korea Using Next-Generation Sequencing

29 views | Apr 29 2023

This study found that retreatment with pan-genotypic DAA was highly successful in Korean patients with chronic HCV infection who failed initial DAA treatment, despite the presence of baseline or treatment-emergent RAS. [Read the Full Post]

JAK inhibitors for rheumatoid arthritis

94 views | Apr 29 2023

JAK inhibitors represent a promising class of drugs for the treatment of rheumatoid arthritis, with varying degrees of selectivity for different JAK isoforms, and precision medicine approaches may enhance their effectiveness in the future. [Read the Full Post]

Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia

46 views | Apr 28 2023

The study found that glucose-induced AKT/mTOR activation promotes AML growth and inhibition of glycolysis may be a potential therapy strategy for AML. [Read the Full Post]

4-octyl itaconate ameliorates alveolar macrophage pyroptosis against ARDS via rescuing mitochondrial dysfunction and suppressing the cGAS/STING pathway

136 views | Apr 28 2023

This study suggests that 4-octyl itaconate has the potential to ameliorate acute respiratory distress syndrome by inhibiting NLRP3-mediated macrophage pyroptosis in a STING/IRF3-dependent manner and rescuing mitochondrial dysfunction. [Read the Full Post]

Safety and immunogenicity of a TK/ gI/gE gene-deleted feline herpesvirus-1 mutant constructed via CRISPR/Cas9 in feline

32 views | Apr 28 2023

The study describes the development of a novel FHV-1 vaccine using CRISPR/Cas9-mediated homologous recombination, which showed improved safety and efficacy compared to the commercial modified live vaccine. [Read the Full Post]

Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer

64 views | Apr 28 2023

A Phase I trial found that the maximally tolerated dose of thymidine plus cisplatin in patients with advanced cancer was 60 g/m2/day, with hematological toxicity being the dose-limiting factor, and recommended this dose for Phase II trials. [Read the Full Post]

The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study

38 views | Apr 28 2023

The study suggests that the controlling nutritional status (CONUT) score is a reliable prognostic indicator in esophageal squamous cell carcinoma (ESCC) patients undergoing neoadjuvant immunochemotherapy (nICT), with a low pretreatment CONUT score associated with a better response to treatment and a lower recurrence rate. [Read the Full Post]